Akouos is a precision genetic medicine company developing gene therapies that restore and preserve hearing. Leveraging its adeno-associated viral vectors (AAV)-based gene therapy platform, Akouos is focused on developing precision therapies for forms of sensorineural hearing loss. Headquartered in Boston, the Company was founded in 2016 by world leaders in the fields of neurotology, genetics, inner ear drug delivery and AAV gene therapy. Akouos has strategic partnerships with Massachusetts Eye and Ear Infirmary and Lonza, Inc.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 08/07/18 | $50,000,000 | Series A |
5AM Ventures New Enterprise Associates Novartis Venture Funds Partners Innovation Fund RA Capital Management Sofinnova Ventures | undisclosed |
